tiprankstipranks
Trending News
More News >

4SC AG Faces Setback as EMA Signals Negative Opinion on Resminostat

Story Highlights
4SC AG Faces Setback as EMA Signals Negative Opinion on Resminostat

Confident Investing Starts Here:

4SC AG ( (DE:VSC) ) has issued an announcement.

4SC AG announced that the European Medicines Agency (EMA) is expected to issue a negative opinion on the Marketing Authorization Application for Resminostat (Kinselby), a treatment for advanced stage cutaneous T-cell lymphoma (CTCL). As a result, 4SC has decided to discontinue the development and commercialization of Resminostat. The company plans to reassess its strategic direction and has assured stakeholders that it has sufficient funds to cover its projected expenses for at least the next 12 months.

More about 4SC AG

4SC AG is a biotechnology company based in Planegg-Martinsried, Germany, focused on developing small molecule drugs for the treatment of cancer and autoimmune diseases. The company is listed on the Frankfurt Stock Exchange and is known for its research and development efforts in oncology.

Average Trading Volume: 1,048

Technical Sentiment Signal: Sell

Current Market Cap: €35.01M

Find detailed analytics on VSC stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App